The impact of herpes zoster and subsequent chronic pain on patients' daily lives

被引：2

作者：

Arnould B. ^{[1
]}

Benmedjahed K. ^{[1
]}

Gallais J.-L. ^{[2
]}

Giniès P. ^{[3
]}

Baron R. ^{[4
]}

机构：

[1] Mapi Values, Lyon 69003

[2] Medical Practice, Paris

[3] Saint Eloi Hospital, Montpellier

[4] Division of Neurological Pain Research and Therapy, Department of Neurology, University Hospital, Schleswig-Holstein

来源：

Journal of Public Health | 2010年 / 18卷 / 6期

关键词：

Conceptual model; Herpes zoster; Pain; Patient-reported outcomes; Post-herpetic neuralgia; Quality of life;

D O I：

10.1007/s10389-010-0346-6

中图分类号：

学科分类号：

摘要：

Aim: The aim of our study was to carry out a literature review and develop a model illustrating the domains of patients' lives that are impacted by herpes zoster (HZ) and subsequent chronic pain. Subjects and methods: Biomedical databases and online congress archives were searched using keywords related to HZ or post-herpetic neuralgia (PHN) and social, psychological or physical impact. A total of 733 abstracts were reviewed, and 29 publications containing concepts reported by patients were retained for the model. Wilson and Cleary's model was used to organise the findings. Links between concepts were documented on three levels: hypothesis, observation and evidence. The final model illustrates the concepts impacted by HZ and PHN, relationships between these concepts and the level of evidence identified. Results: The concepts identified from the articles were grouped into the following categories: biological/physiological, symptom status, functional status, health perceptions, characteristics of the individual, health-related quality of life (HRQOL), treatment and characteristics of the environment. Evidence exists showing that HZ-related pain directly impacts functional status, health perceptions and HRQOL. Conclusion: Patients report that all major domains of life are impaired by HZ or subsequent chronic pain. HZ and its painful and debilitating complications can have a substantial impact on physical, psychological, social and role functioning, HRQOL and activities of daily living. The impact on elderly patients needs to be further assessed with appropriately designed and validated instruments, with specific attention paid to dependence. © 2010 Springer-Verlag.

引用

页码：567 / 574

页数：7

共 59 条

[1]

Acquadro C., Berzon R., Dubois D., Leidy N.K., Marquis P., Revicki D., Rothman M., Incorporating the patient's perspective into drug development and communication: An ad hoc task force report of the patient-reported outcomes (PRO) Harmonization Group meeting at the food and drug administration, February 16, 2001, Value in Health, 6, 5, pp. 522-531, (2003)

[2]

Binder A., Koroschetz J., Baron R., Disease mechanisms in neuropathic itch, Nature Clinical Practice Neurology, 4, 6, pp. 329-337, (2008)

[3]

Bowsher D., The lifetime occurrence of herpes zoster and prevalence of post-herpetic neuralgia: A retrospective survey in an elderly population, Eur J Pain, 3, pp. 335-342, (1999)

[4]

Brisson M., Edmunds W.J., Epidemiology of varicella-zoster virus in England and Wales, Journal of Medical Virology, 70, SUPPL. 1, (2003)

[5]

Chapman R.S., Cross K.W., Fleming D.M., The incidence of shingles and its implications for vaccination policy, Vaccine, 21, 19-20, pp. 2541-2547, (2003)

[6]

Chassany O., Sagnier P., Marquis P., Fullerton S., Aaronson N., Patient-reported outcomes: The example of health-related quality of life - A European guidance document for the improved integration of health-related quality of life assessment in the drug regulatory process, Drug Inf J, 36, pp. 209-238, (2002)

[7]

Chidiac C., Bruxelle J., Daures J.-P., Hoang-Xuan T., Morel P., Leplege A., El Hasnaoui A., De Labareyre C., Characteristics of patients with herpes zoster on presentation to practitioners in France, Clinical Infectious Diseases, 33, 1, pp. 62-69, (2001)

[8]

Clark M.R., Heinberg L.J., Haythornthwaite J.A., Quatrano-Piacentini A.L., Pappagallo M., Raja S.N., Psychiatric symptoms and distress differ between patients with postherpetic neuralgia and peripheral vestibular disease, J Psychosom Res, 48, pp. 51-57, (2000)

[9]

Guideline on Clinical Medicinal Products Intended for the Treatment of Neuropathic Pain, (2007)

[10]

Coplan P.M., Schmader K., Nikas A., Chan I.S.F., Choo P., Levin M.J., Johnson G., Bauer M., Williams H.M., Kaplan K.M., Guess H.A., Oxman M.N., Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: Adaptation of the brief pain inventory, Journal of Pain, 5, 6, pp. 344-356, (2004)

← 1 2 3 4 5 6 →